Prophylactic Antibiotics Decrease Infectious Morbidity in Pediatric AML (7/10/2008)
Researchers from St. Jude Children’s Research Hospital have reported that children with acute myeloid leukemia (AML) benefit from intravenous antibiotic prophylaxis during remission induction therapy. The details of this study appeared in an early online publication on May 5, 2008 in Cancer.

Radiation Therapy for Prostate Cancer Increases Incidence of AML (6/18/2008)
According to a study presented at the 2008 meeting of the American Society of Clinical Oncology, the use of external beam radiation therapy (EBRT) for treatment of prostate cancer is associated with a twofold increase in the risk of developing acute myeloid leukemia (AML).

Quinamed® + ARA-C Effective for Secondary Acute Myeloid Leukemia (6/17/2008)
Researchers from several U.S. Medical Centers have reported that the combination of Quinamed® (amonafide, benzisoquinolinedione, nafidimide) and ara-C is active in the treatment of patients with secondary acute myeloid leukemia (sAML). The details of this Phase II study were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30-June 2.

Molecular Distinctions in AML with Normal Cytogenetics Defined (5/5/2008)
Two recent publications in the May 1, 2008 issue of the New England Journal of Medicine suggest that molecular testing can be of prognostic significance in patients with acute myeloid leukemia (AML) with normal cytogenetics.

Gleevec Improves Outcomes of Philadelphia Chromosome Positive (Ph+) Childhood Acute Lymphoblastic Leukemia (ALL) (12/12/2007)
Researchers affiliated with Children’s Oncology Group (GOG) have reported that the addition of Gleevec® (imatinib mesylate) to high-dose chemotherapy improves event-free survival (EFS) in children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). The details of this study were presented at the 2007 meeting of the American Society of Hematology (ASH), December 8-10, in Atlanta Georgia.